Efficacy of Enzyme and Substrate Reduction Therapy with a Novel Antagonist of Glucosylceramide Synthase for Fabry Disease (Q36025702)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25938659%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

title

Efficacy of Enzyme and Substrate Reduction Therapy with a Novel Antagonist of Glucosylceramide Synthase for Fabry Disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25938659%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25938659%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

7

Robert J Desnick

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25938659%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

author name string

Karen M Ashe

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25938659%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Eva Budman

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25938659%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Dinesh S Bangari

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25938659%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Craig S Siegel

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25938659%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Jennifer B Nietupski

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25938659%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Bing Wang

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25938659%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Ronald K Scheule

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25938659%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

John P Leonard

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25938659%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Seng H Cheng

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25938659%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

language of work or name

English

0 references

publication date

30 April 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25938659%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25938659%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25938659%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

page(s)

389-399

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25938659%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 4.0 International

7 March 2020

copyright license

start time

1 January 2015

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

exact match

https://scigraph.springernature.com/pub.10.2119/molmed.2015.00088

0 references

cites work

Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559530

Agalsidase benefits renal histology in young patients with Fabry disease

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559530

Small fibers in Fabry disease: baseline and follow-up data under enzyme replacement therapy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559530

Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559530

Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559530

Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559530

Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559530

Correction of the biochemical and functional deficits in fabry mice following AAV8-mediated hepatic expression of alpha-galactosidase A.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559530

Long-term safety and efficacy of enzyme replacement therapy for Fabry disease

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559530

Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559530

Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559530

A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559530

Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559530

Colonic involvement in Fabry's disease

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559530

Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559530

Multidimensional analysis of clinical symptoms in patients with Fabry's disease.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559530

Later-onset Pompe disease: early detection and early treatment initiation enabled by newborn screening.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559530

Neurological complications in Fabry disease

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559530

Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559530

Ability of adeno-associated virus serotype 8-mediated hepatic expression of acid alpha-glucosidase to correct the biochemical and motor function deficits of presymptomatic and symptomatic Pompe mice

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559530

Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559530

AAV8-mediated expression of glucocerebrosidase ameliorates the storage pathology in the visceral organs of a mouse model of Gaucher disease.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559530

Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559530

Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559530

Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559530

AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of alpha-galactosidase A and the induction of immune tolerance in Fabry mice.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559530

Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559530

Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559530

Testosterone-responsive mouse kidney glycosphingolipids: developmental and inbred strain effects.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559530

A method for the quantitative determination of neutral glycosphingolipids in urine sediment

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559530

Agalsidase-beta therapy for advanced Fabry disease: a randomized trial

23 September 2018

1 reference

https://api.crossref.org/works/10.2119%2FMOLMED.2015.00088

A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2119%2FMOLMED.2015.00088

Diagnosis of Glycosphingolipidoses by Urinary-Sediment Analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.2119%2FMOLMED.2015.00088

α-Galactosidase A knockout mice: progressive organ pathology resembles the type 2 later-onset phenotype of Fabry disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2119%2FMOLMED.2015.00088

Effective clearance of GL-3 in a human iPSC-derived cardiomyocyte model of Fabry disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2119%2FMOLMED.2015.00088

Colonic involvement in Fabry disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2119%2FMOLMED.2015.00088

Urinary exosomes: is there a future?

31 March 2020

1 reference

https://api.crossref.org/works/10.2119%2FMOLMED.2015.00088

Psychological aspects of patients with Fabry disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2119%2FMOLMED.2015.00088

Factors affecting the glycosphingolipid composition of murine tissues

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25938659

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.2119/MOLMED.2015.00088

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25938659%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

7 March 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25938659%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference